Clinical Trial Update: Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR [Phase 1]

View source ↗

Summary

Phase 1 study assessing bioequivalence of the 300 mg Lamotrigine extended-release formulation and evaluating absence of a food effect.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Lamotrigine-XR (lamotrigine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy | Phase 1 | Status: COMPLETED